Regeneron said it hopes the late-stage drug trial will involve about 2,000 patients across the United States.

再生元公司表示，其希望约2000名美国患者参与药物试验的最后阶段。

Regeneron is launching one of the drug trials jointly with the U.S. National Institute of Allergy and Infectious Diseases.

再生元公司正在与美国国家过敏症和传染病研究所（简称NIAID）联合开展其中一项药物试验。

Regeneron, an American pharma company, is testing drugs that block myostatin and activin, proteins that inhibit muscle growth in the body.

美国制药公司 Regeneron 正在测试阻断肌生长抑制素和激活素（两种抑制人体肌肉生长的蛋白质）的药物。